Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines

Stock News

2025/12/15

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.

Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.

The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1153257892"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153257892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153257892?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 16:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153257892","market":"hk","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.</p>\n<p>Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.</p>\n<p>The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 16:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.</p>\n<p>Hydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.</p>\n<p>The approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"","article_id":"1153257892","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153257892","pubTimestamp":1765786358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0187":"一线龙头","BK0184":"上海国资改革","BK0175":"白马股","BK0097":"医药电商","BK0099":"上海本地重组","BK0028":"国家队","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","02607":"上海医药","BK0012":"证金概念","BK0196":"行业龙头"},"translate_title":"上海医药（601607.SH）：硫酸羟氯喹片获菲律宾药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received a drug registration certificate from the Philippine Food and Drug Administration for its hydroxychloroquine sulfate tablets, approving the drug for market launch.\nHydroxychloroquine sulfate tablets are primarily used to treat rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin conditions triggered or worsened by sunlight.\nThe approval of hydroxychloroquine sulfate tablets (200mg) by the Philippine FDA signifies that the company is now qualified to sell the drug in the Philippine market. This milestone is expected to positively impact Shanghai Pharmaceuticals' overseas expansion efforts while providing valuable experience in international market development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}